Mammoth Biosciences Named to Fierce Medtech’s “Fierce 15” Companies of 2020 for Advancing Next Generation CRISPR Products in Diagnostics and Therapeutics

Mammoth Biosciences today announced that it has been named by Fierce Medtech as one of 2020’s Fierce 15, designating it as one of the most promising private companies in the industry. This designation comes after a year of immense momentum at the company as it leverages its innovative CRISPR platform in the fight against the COVID-19 pandemic and beyond.

As a leader in the development of CRISPR products, Mammoth Biosciences has generated international recognition for its unique approach to diagnostics, genome editing, and protein discovery. The company has made immense strides this year in building its CRISPR toolkit, for example with the exclusive licensing and development of the Casɸ family of proteins, which can enable more expanded delivery options along with precise genome targeting and editing. 

On the diagnostics front, Mammoth reconfigured its DETECTR™ platform at the onset of the pandemic to build the first CRISPR-based test for the novel coronavirus. The company has since partnered with several leading healthcare companies including GSK Consumer Healthcare, MilliporeSigma, Hamilton Company, and Agilent Technologies to further develop the CRISPR diagnostics technology and to help fill the testing gap. The company was awarded two contracts from the Defense Advanced Research Projects Agency (DARPA) and the National Institutes of Health (NIH) to develop and commercialize CRISPR-based diagnostics and biosurveillance platforms for COVID-19 and other infectious diseases. Altogether, the company’s efforts over the past year have advanced its ultimate goal of improving broad access to accurate, scalable, and affordable testing. 

“Fierce Medtech and the broader Questex team provide an invaluable service to the life sciences industry by providing in-depth journalism on the issues that matter,” Trevor Martin, CEO and co-founder of Mammoth Biosciences. “We’re honored to receive this recognition and look forward to helping improve people’s health through leveraging CRISPR’s power to read and write the code of life.”

The Fierce 15 celebrates the spirit of being “fierce” — championing innovation and creativity, even in the face of intense competition.  This is Fierce Medtech’s 9th annual Fierce 15 selection. This year’s full list of winners can be viewed online at https://www.fiercebiotech.com/special-report/fierce-medtech-s-2020-fierce-15.

“Each member of this year’s class of Fierce 15 stands out in a different way, but they all overcame a year of unforgettable obstacles, making each of their successes that much more significant — and all have the potential to deliver changes in healthcare that promise to outlast this pandemic,” said Conor Hale, associate editor of Fierce Medtech.

An internationally recognized daily report reaching a network of over 90,000 med tech industry professionals, Fierce Medtech provides subscribers with an authoritative analysis of the day’s top stories. Every year Fierce Medtech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

Companies and people interested in learning more about Mammoth’s CRISPR-based platform should go to www.mammoth.bio/. 

About Mammoth Biosciences 

Mammoth Biosciences, Inc. is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. By leveraging its internal research and development and exclusive licensing to patents related to Cas12, Cas13, Cas14 and CasΦ, Mammoth Biosciences can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in Brisbane, California, Mammoth Biosciences is co-founded by Nobel Prize winner and CRISPR pioneer Jennifer Doudna as well as Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Decheng, Mayfield, NFX, and 8VC, and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.

About Fierce Medtech

Fierce Medtech keeps biopharma executives, device developers, engineers, and researchers updated on the must-know news, trends and developments in medical technology.  More than 90,000 top industry professionals rely on Fierce Medtech for an insider briefing on the day’s top stories.

Contact Information

Riley Munks

Press Contact

VSC for Mammoth Biosciences

mammoth@vsc.co